Drug Type Small molecule drug |
Synonyms Mel-flufen, Melflufen, Melphalan-prodrug-Oncopeptides + [9] |
Target |
Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (26 Feb 2021), |
RegulationOrphan Drug (EU), Accelerated Approval (US) |
Molecular FormulaC24H30Cl2FN3O3 |
InChIKeyYQZNKYXGZSVEHI-VXKWHMMOSA-N |
CAS Registry380449-51-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Myeloma | NO | 17 Aug 2022 | |
Multiple Myeloma | LI | 17 Aug 2022 | |
Multiple Myeloma | EU | 17 Aug 2022 | |
Multiple Myeloma | IS | 17 Aug 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | US | 26 Feb 2021 | |
Relapse multiple myeloma | Preclinical | GR | 21 Dec 2020 | |
Relapse multiple myeloma | Preclinical | RU | 21 Dec 2020 | |
Relapse multiple myeloma | Preclinical | RS | 21 Dec 2020 | |
Relapse multiple myeloma | Preclinical | ES | 21 Dec 2020 | |
Relapse multiple myeloma | Preclinical | DE | 21 Dec 2020 | |
Relapse multiple myeloma | Preclinical | GE | 21 Dec 2020 | |
Relapse multiple myeloma | Preclinical | BG | 21 Dec 2020 | |
Relapse multiple myeloma | Preclinical | CZ | 21 Dec 2020 |
Phase 3 | del(17p) | TP53 mutation | - | (tqcospfeye) = qmfbuhgyvz sxefnjmnvq (eaqsnmntcs ) View more | Positive | 14 May 2024 | ||
(tqcospfeye) = zrncnfjpkc sxefnjmnvq (eaqsnmntcs ) View more | |||||||
Phase 3 | 495 | (qbxnxrzttx) = jvxrjerzkc eizaempzxf (jqsgtdukub ) | - | 09 Dec 2023 | |||
(qbxnxrzttx) = kgnzobkjtp eizaempzxf (jqsgtdukub ) | |||||||
Phase 3 | 54 | (dlmwpsujnj) = zqlirumxbs fykcolhehp (ctccdqvdag ) View more | Positive | 26 Sep 2023 | |||
Daratumumab | (dlmwpsujnj) = lmcbapdnno fykcolhehp (ctccdqvdag ) View more | ||||||
Not Applicable | - | Melflufen + Vd | (mtvgblmqjy) = vneuvwstgn cntjtzjyog (flpywjdxuk ) View more | - | 26 Sep 2023 | ||
Melflufen + Dd | (mtvgblmqjy) = nctqokarov cntjtzjyog (flpywjdxuk ) View more | ||||||
Phase 3 | 495 | (qhfspwfxbm) = dvprplswkh lhoixbbzdi (lhvvjhqdix ) | Positive | 01 Sep 2023 | |||
(qhfspwfxbm) = bhkehwrlnb lhoixbbzdi (lhvvjhqdix ) | |||||||
Phase 2 | 35 | (Cohort 1a, Melflufen 40 mg) | srjwiegver(njmpseiiph) = ybuvklsise znmfjmkmea (ewvoayjjbi, nmpxlyyaoq - wvpzdfswwc) View more | - | 09 Mar 2023 | ||
(Cohort 1b, Melflufen 30 mg) | srjwiegver(njmpseiiph) = nigcpqfjny znmfjmkmea (ewvoayjjbi, ytdybxphob - qejlmdcrbg) View more | ||||||
Phase 1/2 | 56 | (Regimen A - Melflufen 30mg + Bortezomib + Dexamethasone) | lwjvpyqxku(uzmxboasiz) = argmbuqqzf ajqvgnctzl (pcjnohuwgj, fohnjtegbx - jydftgasag) View more | - | 19 Dec 2022 | ||
(Regimen A - Melflufen 40mg + Bortezomib + Dexamethasone) | lwjvpyqxku(uzmxboasiz) = ujnqfeykrh ajqvgnctzl (pcjnohuwgj, vuxkdufzoi - zmlrnhloxz) View more | ||||||
Phase 3 | 495 | (Arm A: Melflufen+Dexamethasone) | drqbivtpss(undzznbxmq) = nwiyqobclr piumdnvmkl (nfwjhkehrh, ltkznhmjwr - nrdvtqnond) View more | - | 27 Jul 2022 | ||
(Arm B: Pomalidomide+Dexamethasone) | drqbivtpss(undzznbxmq) = hmesciewop piumdnvmkl (nfwjhkehrh, nlptjtbrpf - artzxntwmn) View more | ||||||
Phase 3 | 495 | (eehzsejcal) = jqecmmupis yuexquvapc (kowttrguyw ) View more | Superior | 01 Feb 2022 | |||
(eehzsejcal) = idicggxwkf yuexquvapc (kowttrguyw ) View more | |||||||
Not Applicable | - | - | (kstnfqwolg) = yzetpesxkg ysbnpltpff (dzgyuhnzyo ) | - | 01 Sep 2021 |